高级检索
当前位置: 首页 > 详情页

Curcumol repressed cell proliferation and angiogenesis via SP1/mir-125b-5p/VEGFA axis in non-small cell lung cancer

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]The Postdoctoral Research Station, Guangdong Provincial Hospital of Chinese Medicine, The SecondClinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China, [2]GuangDong Academy of Traditional Chinese Medicine, Research Team of Bio-molecular and SystemBiology of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China, [3]Central Laboratory, Hunan Provincial Hospital of Integrated Traditional Chinese and WesternMedicine, The Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine, Changsha,China, [4]Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese MedicineSyndrome, Guangzhou, China, [5]Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine andImmune Disease Research, Guangzhou University of Chinese Medicine, Guangzhou, China, [6]Department of Emergency, The Affiliated TCM Hospital of Guangzhou Medical University,Guangzhou, China, [7]State Key Laboratory of Dampness Syndrome of Chinese Medicine, The SecondAffiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
出处:
ISSN:

关键词: curcumol NSCLC Sp1 miR-125b-5p VEGFA angiogenesis tumor microenvironment

摘要:
NSCLC (non-small cell lung cancer) is one of the most common and lethal malignant tumors, with low 5-year overall survival rate. Curcumol showed antitumor activity in several cancers, but evidence about its effect on NSCLC remains unclear. In the present study, we found that Curcumol markedly inhibited NSCLC cells proliferation, migration and invasion. Endothelial cells are an important part of tumor microenvironment. Tube formation assay and wound healing assay indicated that A549 derived conditioned medium affected HUVECs (human umbilical vein endothelial cells). Mechanistically, Curcumol downregulated the expression of SP1 (specificity protein 1) while upregulated miR-125b-5p, followed by decreasing VEGFA expression in NSCLC cells. Furthermore, overexpression of SP1 partially reversed the inhibitory effect of Curcumol on A549 and H1975 cell viability and VEGFA expression. Inhibition of miR-125b-5p presented similar effect. Interestingly, there was mutual modulation between SP1 and miR-125b-5p. Collectively, our study revealed that Curcumol inhibited cell growth and angiogenesis of NSCLC in vitro and in vivo, possibly through SP1/miR-125b-5p/VEGFA regulatory mechanism. These findings may provide effective therapy strategies for NSCLC treatment.Copyright © 2022 Ma, Tang, Tang, Wang, Zhang, Lu, Wu and Han.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 2 区 医学
小类 | 2 区 药学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 药学
JCR分区:
出版当年[2020]版:
Q1 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]The Postdoctoral Research Station, Guangdong Provincial Hospital of Chinese Medicine, The SecondClinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China, [2]GuangDong Academy of Traditional Chinese Medicine, Research Team of Bio-molecular and SystemBiology of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China,
通讯作者:
通讯机构: [2]GuangDong Academy of Traditional Chinese Medicine, Research Team of Bio-molecular and SystemBiology of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China, [4]Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese MedicineSyndrome, Guangzhou, China, [5]Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine andImmune Disease Research, Guangzhou University of Chinese Medicine, Guangzhou, China, [7]State Key Laboratory of Dampness Syndrome of Chinese Medicine, The SecondAffiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2022 今日访问量:0 总访问量:648 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号